AKBA · Categories · Form 4

AKBA - SEC Form 4 insider transactions

Akebia Therapeutics Inc. (AKBA) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.

Recent Form 4 for AKBA

• 67d
  SEC Form 4 filed by Vickers Philip J.

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 125d
  SVP, Chief Accounting Officer Malabre Richard C sold $68,838 worth of shares (49,524 units at $1.39), decreasing direct ownership by 14% to 299,390 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 125d
  Chief Commercial Officer Grund Nicholas sold $117,912 worth of shares (84,829 units at $1.39), decreasing direct ownership by 13% to 561,750 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 125d
  SVP, Chief Medical Officer Burke Steven Keith sold $94,045 worth of shares (67,658 units at $1.39), decreasing direct ownership by 7% to 948,432 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 125d
  SVP, Chief Legal Officer Rucci Carolyn M. sold $96,983 worth of shares (69,772 units at $1.39), decreasing direct ownership by 11% to 588,378 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 125d
  SVP, CFO, CBO & Treasurer Ostrowski Erik sold $48,582 worth of shares (34,951 units at $1.39), decreasing direct ownership by 5% to 672,635 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 125d
  CEO and President Butler John P. sold $474,414 worth of shares (341,305 units at $1.39) and was granted 175,250 shares, decreasing direct ownership by 5% to 3,297,794 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 126d
  Chief Commercial Officer Grund Nicholas was granted 204,000 shares, increasing direct ownership by 46% to 646,579 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 126d
  SVP, Chief Medical Officer Burke Steven Keith was granted 204,000 shares, increasing direct ownership by 25% to 1,016,090 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 126d
  SVP, Chief Legal Officer Rucci Carolyn M. was granted 190,000 shares, increasing direct ownership by 41% to 658,150 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 126d
  SVP, Chief Accounting Officer Malabre Richard C was granted 79,000 shares, increasing direct ownership by 29% to 348,914 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 126d
  SVP, CFO, CBO & Treasurer Ostrowski Erik was granted 204,000 shares, increasing direct ownership by 41% to 707,586 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 126d
  CEO and President Butler John P. was granted 743,000 shares, increasing direct ownership by 27% to 3,463,849 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 343d
  SVP, CFO, CBO & Treasurer Ostrowski Erik sold $151,622 worth of shares (41,314 units at $3.67), decreasing direct ownership by 8% to 503,586 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 363d
  Director Zumwalt Leanne M was granted 35,700 shares, increasing direct ownership by 48% to 109,400 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 363d
  Director Adams Adrian was granted 35,700 shares, increasing direct ownership by 22% to 200,500 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 363d
  Director Wolf Myles was granted 35,700 shares, increasing direct ownership by 37% to 133,381 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 363d
  Director Smith Cynthia was granted 35,700 shares, increasing direct ownership by 29% to 160,933 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 363d
  Director Rogers Michael W was granted 35,700 shares, increasing direct ownership by 28% to 161,729 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 363d
  Director Gilman Steven C was granted 35,700 shares, increasing direct ownership by 30% to 152,830 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 363d
  Director Frieson Ron was granted 35,700 shares, increasing direct ownership by 38% to 129,500 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 363d
  SVP, Chief Accounting Officer Malabre Richard C exercised 15,000 shares at a strike of $1.68 and sold $60,150 worth of shares (15,000 units at $4.01) (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 369d
  SVP, Chief Accounting Officer Malabre Richard C sold $47,069 worth of shares (13,334 units at $3.53), decreasing direct ownership by 5% to 266,914 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 462d
  CEO and President Butler John P. sold $84,928 worth of shares (46,409 units at $1.83), decreasing direct ownership by 2% to 2,557,921 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 462d
  SVP, Chief Medical Officer Burke Steven Keith sold $13,074 worth of shares (7,144 units at $1.83), decreasing direct ownership by 0.88% to 809,090 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 490d
  CEO and President Butler John P. was granted 701,000 shares and sold $302,925 worth of shares (144,250 units at $2.10), increasing direct ownership by 27% to 2,604,330 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 490d
  SVP, Chief Medical Officer Burke Steven Keith was granted 194,900 shares and sold $106,063 worth of shares (50,506 units at $2.10), increasing direct ownership by 21% to 816,234 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 490d
  SVP, Chief Accounting Officer Malabre Richard C was granted 85,000 shares and sold $63,424 worth of shares (30,202 units at $2.10), increasing direct ownership by 24% to 280,248 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 490d
  Chief Commercial Officer Grund Nicholas was granted 194,900 shares and sold $116,804 worth of shares (55,621 units at $2.10), increasing direct ownership by 46% to 442,579 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 490d
  SVP, CFO, CBO & Treasurer Ostrowski Erik was granted 194,900 shares, increasing direct ownership by 56% to 544,900 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 503d
  Director Frieson Ron exercised 20,100 shares at a strike of $0.45, increasing direct ownership by 27% to 93,800 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 707d
  SVP, CFO, CBO & Treasurer Ostrowski Erik was granted 350,000 shares (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 729d
  Director Wolf Myles was granted 30,000 shares, increasing direct ownership by 44% to 97,681 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 729d
  Director Smith Cynthia was granted 30,000 shares, increasing direct ownership by 32% to 125,233 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 729d
  Director Rogers Michael W was granted 30,000 shares, increasing direct ownership by 31% to 126,029 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 729d
  Director Gilman Steven C was granted 30,000 shares, increasing direct ownership by 34% to 117,130 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 729d
  Director Frieson Ron was granted 30,000 shares, increasing direct ownership by 69% to 73,700 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 729d
  Director Zumwalt Leanne M was granted 30,000 shares, increasing direct ownership by 69% to 73,700 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 729d
  Director Adams Adrian was granted 30,000 shares, increasing direct ownership by 22% to 164,800 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 756d
  Hadas Nicole R. sold $15,140 worth of shares (12,016 units at $1.26), decreasing direct ownership by 2% to 651,243 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 756d
  Dahan Michel sold $43,898 worth of shares (34,840 units at $1.26), decreasing direct ownership by 5% to 672,092 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 761d
  Burke Steven Keith sold $31,050 worth of shares (27,000 units at $1.15), decreasing direct ownership by 4% to 668,840 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 830d
  Dahan Michel sold $13,684 worth of shares (8,661 units at $1.58), decreasing direct ownership by 1% to 706,932 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 830d
  Hadas Nicole R. sold $9,439 worth of shares (5,974 units at $1.58), decreasing direct ownership by 0.89% to 663,259 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 830d
  Butler John P. sold $73,581 worth of shares (46,570 units at $1.58), decreasing direct ownership by 2% to 2,044,580 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 830d
  Burke Steven Keith sold $11,327 worth of shares (7,169 units at $1.58), decreasing direct ownership by 1% to 695,840 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 831d
  Hadas Nicole R. sold $11,265 worth of shares (7,411 units at $1.52), decreasing direct ownership by 1% to 669,233 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 831d
  Dahan Michel sold $16,331 worth of shares (10,744 units at $1.52), decreasing direct ownership by 1% to 715,593 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 831d
  Burke Steven Keith sold $12,718 worth of shares (8,367 units at $1.52), decreasing direct ownership by 1% to 703,009 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 831d
  Butler John P. sold $57,354 worth of shares (37,733 units at $1.52), decreasing direct ownership by 2% to 2,091,150 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 858d
  Grund Nicholas was granted 303,300 shares (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 858d
  Malabre Richard C was granted 223,950 shares (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 858d
  Dahan Michel was granted 149,300 shares, increasing direct ownership by 26% to 726,337 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 858d
  Hadas Nicole R. was granted 149,300 shares, increasing direct ownership by 28% to 676,644 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 858d
  Snow Ellen was granted 149,300 shares, increasing direct ownership by 40% to 519,300 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 858d
  Butler John P. was granted 603,500 shares and sold $78,102 worth of shares (46,489 units at $1.68), increasing direct ownership by 35% to 2,128,883 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 858d
  Burke Steven Keith sold $40,842 worth of shares (24,311 units at $1.68) and was granted 202,200 shares, increasing direct ownership by 33% to 711,376 units (SEC Form 4)

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 1043d
  SEC Form 4: Snow Ellen was granted 370,000 shares

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 1097d
  SEC Form 4 filed by Rogers Michael W

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)
• 1097d
  SEC Form 4 filed by Zumwalt Leanne M

  4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

Other AKBA categories

• 8-K
• 10-K
• 10-Q
• S-1
• 13D
• 13G
• Form 3
• Form 5
• DEF 14A
• M&A
• Earnings
• Dividends